<DOC>
	<DOCNO>NCT02212925</DOCNO>
	<brief_summary>To investigate safety , tolerability , pharmacokinetics , pharmacodynamics BI 14332 CL follow administration multiple rise oral dos 10 day patient type 2 diabetes .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Multiple Rising Oral Doses BI 14332 CL Tablet Female Male Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male postmenopausal hysterectomised female patient proven diagnosis type 2 diabetes mellitus treat diet exercise , one oral hypoglycaemic agent besides glitazones take maximum approve dose Glycosylated haemoglobin A1 ( HbA1c ) ≥ 6.5 % ≤ 8.5 % screen patient treat diet exercise and/or one oral hypoglycaemic agent Age ≥21 Age ≤70 year ( female hysterectomised male patient ) Age ≥60 Age ≤70 year ( female postmenopausal patient ) Body Mass Index ( BMI ) ≥18.5 BMI ≤35 kg/m2 Any find medical examination ( include BP , pulse rate ( PR ) ECG ) deviate normal acceptable clinical relevance Clinically relevant concomitant disease like renal insufficiency , cardiac insufficiency New York Heart Association ( NYHA ) IIIV , myocardial infarction , know cardiovascular disease include hypertension &gt; 140/90 mmHg , stroke transient ischemic attack Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder besides type 2 diabetes , hyperlipidaemia medically treat hypertension Diseases central nervous system ( epilepsy ) psychiatric disorder relevant neurological disorder besides polyneuropathy Chronic relevant acute infection ( e.g . HIV , Hepatitis ) History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial except allow comedication Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Antidiabetic treatment one oral hypoglycaemic agent insulin glitazones antihypertensive treatment verapamil diltiazem Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 40 g/day = 5 units/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Use drug might reasonably influence result trial prolong QT/QTc interval base knowledge time protocol preparation within 10 day prior administration trial Any laboratory value outside reference range clinical relevance acceptable ( value three time higher upper limit normal range e.g . liver enzymes ) Change drug dosing allow comedication ( antihypertensive agent , acetylic salicylic acid statin ) within last 3 month Fasted blood glucose &gt; 240 mg/dl ( &gt; 13.3 mmol/L ) two consecutive day washout Serum creatinine upper limit normal screen Male patient willing use adequate contraception ( condom use plus another form contraception e.g . spermicide , oral contraceptive take female partner , sterilisation , intrauterine device ) whole study period time first intake study drug one month last intake A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m ) A history additional risk factor Torsade de Pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) For female patient : Child bear potential Positive pregnancy test Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>